OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Stein on Recent Treatment Advances in AML

March 6th 2019

Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses recent advances that have been made in the treatment of patients with acute myeloid leukemia (AML).

Dr. Kaplan on a Study With Combination Immune Macrophage Checkpoint Blockade in Lymphoma

March 6th 2019

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib study with combination immune macrophage checkpoint blockade in indolent lymphoma.

Dr. Jacobs on Treating Graft-Versus-Host-Disease With Ibrutinib in CLL

March 6th 2019

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in treating chronic graft-versus-host disease in patients with chronic lymphocytic leukemia (CLL).

Dr. Wakelee on Unmet Needs for Immunotherapy in NSCLC

March 6th 2019

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses unmet needs for immunotherapy in the treatment of patients with non–small cell lung cancer.

Dr. Balar Discusses KEYNOTE-057 Study in NMIBC

March 6th 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses findings from the KEYNOTE-057 study presented at the 2019 Genitourinary Cancers Symposium.

Dr. Marshall on Personalized Chemotherapy in CRC

March 5th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses personalized chemotherapy in the treatment of patients with colorectal cancer.

Dr. Leath on Challenges With Bevacizumab in Cervical Cancer

March 5th 2019

Charles A. Leath, III, MD, gynecologic oncologist, The University of Alabama at Birmingham, discusses challenges with bevacizumab in the treatment of patients with cervical cancer.

Dr. Park Discusses Use of CAR T Cells in ALL

March 5th 2019

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the use of CAR T cells in the treatment of patients with acute lymphoblastic leukemia.

Dr. Katz on Preoperative Chemoradiation in Localized Pancreatic Cancer

March 5th 2019

Matthew H.G. Katz, MD, FACS, associate professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses preoperative chemoradiation for the treatment of patients with localized pancreatic cancer.

Dr. Cortes on Exploring the Use of Quizartinib in AML

March 5th 2019

Jorge E. Cortes, MD, deputy chair of the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the data from the QuANTUM-R trial presented at the 2018 ASH Annual Meeting in relapsed/refractory acute myeloid leukemia (AML).

Dr. Denduluri on Treatment for ER+/HER2- Breast Cancer

March 5th 2019

Neelima Denduluri, MD, medical oncologist, Virginia Cancer Specialists, discusses treatment for patients with estrogen receptor (ER)-positive, HER2-negative breast cancer.

Dr. Campos Discusses Differences Between PARP Inhibitors in Recurrent Ovarian Cancer

March 5th 2019

Susana Campos, MD, MPH, assistant professor of medicine, Harvard Medical School, and Dana-Farber Cancer Institute, discusses differences between PARP inhibitors in recurrent ovarian cancer.

Dr. Chari Discusses Frail and Elderly Patients With Multiple Myeloma

March 2nd 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses frail and elderly patients with multiple myeloma.

Dr. Mix on Local Consolidative Therapy in Oligometastatic NSCLC

March 2nd 2019

Michael D. Mix, MD, assistant professor of radiation oncology at Upstate University Hospital, discusses the use of local consolidative therapy in patients with oligometastatic non–small cell lung cancer (NSCLC).

Dr. Hamilton on the Optimal Duration of Trastuzumab in HER2+ Breast Cancer

March 2nd 2019

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the optimal duration of trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Dr. Fleming Discusses Importance of QoL in Prostate Cancer

March 2nd 2019

Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, associate chair, Genitourinary Research Committee, US Oncology Network, discusses the focus on quality of life in recent prostate cancer clinical trials.

Dr. Wang Discusses Promise of Venetoclax in MCL

March 2nd 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Rini Discusses Tivozanib in Advanced RCC

March 2nd 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential for tivozanib in patients with advanced renal cell carcinoma.

Dr. De Censi Discusses the Results of the Phase III TAM-01 Trial in Breast Cancer

March 1st 2019

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the results of the phase III TAM-01 trial in breast cancer.

Dr. Lindeman on Rationale for a Phase Ib Trial of Venetoclax and Tamoxifen in Breast Cancer

March 1st 2019

Geoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax (Venclexta) combined with tamoxifen in estrogen receptor-positive and BCL-2–positive metastatic breast cancer.